The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6601 - 6601

Published: June 15, 2024

In oral squamous cell carcinoma (OSCC) tissues, an immunotolerant situation triggered by immune checkpoints (ICPs) can be observed. Immune checkpoint inhibitors (ICIs) against the PD1/PD-L axis are used with impressive success. However, response rate is low and development of acquired resistance to ICI treatment Therefore, new strategies especially involving immunological combination therapies need developed. The novel negative BTLA has been suggested as a potential biomarker target for antibody-based immunotherapy. Moreover, improved rates could displayed tumor patients when antibodies directed were in anti-PD1/PD-L1 therapies. aim study was check whether overexpressed OSCC tissues compared healthy mucosa (NOM) diagnostic OSCC. addition, correlation analyses expression other should clarify more precisely potentially useful A total 207 tissue samples divided into 2 groups included study. test group comprised 102 Oral mucosal from 105 volunteers served control group. two isoforms (BTLA-1/2), well PD1, PD-L1/2 CD96 analyzed RT-qPCR. Additionally, proteins detected IHC. Expression levels between groups, relative differences calculated, statistical relevance determined. Furthermore, correlated each other. significantly increased NOM (pBTLA_1 = 0.003; pBTLA_2 0.0001, pIHC 0.003). its ligands PD-L1 PD-L2, CD96, also (p ≤ 0.001). There strong positive that < 0.001; ρ ≥ 0.5). appears relevant local Thus, candidates immunotherapies, CD96.

Language: Английский

PD-1 blockade synergizes with ascorbic acid to restore the activation and anti-viral immune functions of CD8+ T cells in a mouse model of BVDV infection

Veterinary Microbiology, Journal Year: 2024, Volume and Issue: 300, P. 110316 - 110316

Published: Nov. 24, 2024

Language: Английский